
Natera (NTRA) Stock Forecast & Price Target
Natera (NTRA) Analyst Ratings
Bulls say
Natera Inc has demonstrated significant growth potential, with a projected 60% increase in clinical volume for its Signatera test in 2024, fueled by expanding payor coverage and higher recognized average selling prices (ASPs). The company's gross margins have improved markedly from the low 40s to approximately 60%, driven by a favorable product mix and recent enhancements in reimbursement rates, particularly for oncology tests. Additionally, Natera's robust performance during challenging market conditions, with revenues nearly sextupling since 2019, solidifies its position as a leader in the non-invasive prenatal testing and molecular residual disease markets, creating a solid foundation for future expansion in the $30 billion cancer screening total addressable market.
Bears say
Natera's recent quarterly performance fell short of expectations, primarily due to disruptions from electronic medical record (EMR) integration and seasonal holiday effects, which raises concerns about continued revenue growth. The company's 2025 revenue guidance is approximately $28.3 million below consensus, indicating potential challenges in achieving profitability, especially if payors reduce or eliminate reimbursement for its diagnostic services. Additionally, anticipated margin erosion from pricing pressures and the low enterprise value-to-sales ratio further underlines the financial risks facing Natera's future performance.
This aggregate rating is based on analysts' research of Natera and is not a guaranteed prediction by Public.com or investment advice.
Natera (NTRA) Analyst Forecast & Price Prediction
Start investing in Natera (NTRA)
Order type
Buy in
Order amount
Est. shares
0 shares